SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CASTELLAZZI, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.338
AS - Asia 4.712
EU - Europa 3.272
SA - Sud America 775
AF - Africa 79
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 14
Totale 19.209
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.170
SG - Singapore 1.766
CN - Cina 1.578
BR - Brasile 683
IT - Italia 585
UA - Ucraina 529
HK - Hong Kong 520
DE - Germania 516
PL - Polonia 456
GB - Regno Unito 354
TR - Turchia 354
FI - Finlandia 235
VN - Vietnam 171
SE - Svezia 161
RU - Federazione Russa 133
CA - Canada 80
MX - Messico 75
ID - Indonesia 70
AT - Austria 64
IN - India 58
FR - Francia 50
ZA - Sudafrica 47
AR - Argentina 39
CZ - Repubblica Ceca 39
JP - Giappone 39
NL - Olanda 38
BE - Belgio 32
BD - Bangladesh 26
IR - Iran 23
ES - Italia 21
IQ - Iraq 19
AU - Australia 18
LT - Lituania 15
CO - Colombia 14
PY - Paraguay 13
KR - Corea 12
UZ - Uzbekistan 12
A2 - ???statistics.table.value.countryCode.A2??? 8
EC - Ecuador 8
EG - Egitto 8
AE - Emirati Arabi Uniti 7
PT - Portogallo 7
SA - Arabia Saudita 7
UY - Uruguay 7
EU - Europa 6
IE - Irlanda 6
KE - Kenya 6
KZ - Kazakistan 6
PK - Pakistan 6
RO - Romania 6
IL - Israele 5
MA - Marocco 5
VE - Venezuela 5
AZ - Azerbaigian 4
BG - Bulgaria 4
ET - Etiopia 4
HN - Honduras 4
JO - Giordania 4
NP - Nepal 4
DO - Repubblica Dominicana 3
HU - Ungheria 3
KG - Kirghizistan 3
OM - Oman 3
PE - Perù 3
PH - Filippine 3
AL - Albania 2
AO - Angola 2
CI - Costa d'Avorio 2
CL - Cile 2
GR - Grecia 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TW - Taiwan 2
AM - Armenia 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
CH - Svizzera 1
DZ - Algeria 1
EE - Estonia 1
GD - Grenada 1
GE - Georgia 1
HR - Croazia 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MK - Macedonia 1
MN - Mongolia 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
QA - Qatar 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
Totale 19.208
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.121
Ashburn 1.056
Fairfield 905
Singapore 859
Chandler 714
Houston 592
Beijing 572
Jacksonville 561
Santa Clara 521
Hong Kong 520
Warsaw 441
Ann Arbor 391
Seattle 328
Wilmington 328
Cambridge 294
Dallas 228
Izmir 223
Ferrara 219
New York 190
Nanjing 187
Los Angeles 179
Princeton 153
Munich 130
Milan 126
Boardman 107
Shanghai 92
San Diego 87
Dearborn 77
São Paulo 69
Addison 65
Helsinki 59
Ho Chi Minh City 58
Turku 57
Jakarta 56
Nanchang 55
Mexico City 53
Tianjin 51
Vienna 51
Shenyang 48
Bremen 47
London 47
Brooklyn 45
Buffalo 44
Hebei 42
Jiaxing 42
Changsha 41
Chicago 37
Norwalk 37
Tokyo 37
Hefei 33
Brussels 32
Chennai 32
Phoenix 32
Stockholm 32
Denver 31
The Dalles 31
Montreal 30
Brno 29
Hanoi 28
Johannesburg 27
Falls Church 26
Moscow 25
Orem 24
Toronto 24
Boston 23
Redwood City 22
San Mateo 21
Dong Ket 20
Jinan 20
Ningbo 20
San Francisco 20
Auburn Hills 19
Orange 19
Poplar 19
Rio de Janeiro 19
Zhengzhou 19
Nuremberg 18
Mountain View 17
Atlanta 16
Bologna 16
Guangzhou 16
Washington 16
Belo Horizonte 15
Brasília 15
Falkenstein 15
Kunming 15
Frankfurt am Main 14
Ankara 12
Columbus 12
Manchester 12
Amsterdam 11
Curitiba 11
Des Moines 11
Tappahannock 11
Tashkent 11
Verona 11
Charlotte 10
Indiana 10
Ottawa 10
Salvador 10
Totale 13.234
Salva come PNG Salva come JPEG
Nome #
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment 379
Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals 227
A Commentary on the Use of Epstein-Barr Virus Specific Antibodies as Biological Markers in Multiple Sclerosis 223
Decreased Arylesterase activity of Paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases 222
Multiple Sclerosis in Italy: A 40-Year Follow-Up of the Prevalence in Ferrara 221
Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients 209
TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis 208
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker 200
Epstein-Barr virus and Multiple Sclerosis: in-depth analysis of the virus-specific antibody response at the time of diagnosis and during therapy 199
Comparison of antibodies with amylase activity from cerebrospinal fluid and serum of patients with multiple sclerosis 196
Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer's disease and mild cognitive impairment 191
Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis 190
Chlamydia pneumoniaespecific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms 189
Timing of serum active MMP-9 and MMP-2 levels in acute and subacute phases after spontaneous intracerebral hemorrhage 189
Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules 187
Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis 186
Comparison of DNA-Hydrolyzing Antibodies from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis 183
Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis 182
Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies 178
Emerging topics and new perspectives on HLA-G 176
Matrix metalloproteinase 9 as a marker of disease activity in multiple sclerosis 174
Epidemiological health and social study on multiple sclerosis in the Ferrara province 173
Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis 171
Assessment of HIV-intrathecal humoral immune response in AIDS-related neurological disorders 171
Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients 166
Correlation between auto/mitophagic processes and magnetic resonance imaging activity in multiple sclerosis patients 164
A Further Evidence Of Pathogenic Role Of Chlamydia Pneumoniae In Multiple Sclerosis 162
Cerebrospinal fluid analysis and the determination of oligoclonal bands 160
A new developed culture method efficiently supports the growth of Chamydia pneumoniae in PBMC and CSF samples from patients with Multiple Sclerosis 157
Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis 156
Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. 154
A proteomic approach to detect gelatinases levels and their inhibitors in patients with neurological diseases 153
An overview on the relationship between Epstein-Barr virus and multiple sclerosis 152
Affinity distribution of anti-EBV IgG in the cerebrospinal fluid of patients with multiple sclerosis and in controls 151
25-hydroxyvitamin D in cerebrospinal fluid from patients with multiple sclerosis 149
Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis 148
Clinical and MRI activity are associated to elevated cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-9 in multiple sclerosis patients 146
Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy 146
CEREBROSPINAL FLUID AND SERUM LEVELS OF ANTI-CHLAMYDIA PNEUMONIAE IGA IN PATIENTS WITH MULTIPLE SCLEROSIS 146
Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms 145
Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding 144
Intrathecal levels of vitamin D and IgG in multiple sclerosis 143
Effect of pH on MMP-9 release by LPS-stimulated neutrophils 142
DNA Sequences of Parachlamydia-like organisms in CSF of Patients with Neurological Disorders 141
ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR IMPLEMENTING A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES Identification of a TIMP-1-resistant active MMP-9 in serum of Multiple Sclerosis patients 140
Neurofilament ELISA validation 140
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 are elevated in in multiple sclerosis patients with disease activity 140
25 hydroxyvitamin D in cerebrospinal fluid from patients with multiple sclerosis during relapse and remission 135
Biomolecular and immunological diagnostic aspects of toxoplasmosis during AIDS. 135
Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis 135
Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings 135
ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR THE IMPLEMENTATION A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES IN MS. 133
Increased age and male sex are independently associated with higher frequency of blood-cerebrospinal fluid barrier dysfunction using the albumin quotient 133
Quantification of CSF and serum levels and intrathecal synthesis of anti-EBV antibodies in patients with multiple sclerosis and with other neurological disorders. 133
Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients 132
Timing of Serum Soluble HLA-G Levels in Acute and Subacute Phases After Spontaneous Intracerebral Hemorrhage 130
Analysis of MMP-9 in CSF and sera of patients with neurological diseases 129
Elevated CSF and serum levels and intrathecal synthesis of active MMP-2 in MS patients with no evidence of MRI disease activity 126
Altered miRNA expression in T regulatory cells in course of multipla sclerosis 126
Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms 124
Matrix Metalloproteinases as a Pleiotropic Biomarker in Medicine and Biology 122
Altered miRNA expression in T regulatory cells in course of multiple sclerosis 121
An evaluation of quantitative env and qualitative pol rt-pcr detection of the multiple sclerosis (MS) -associated retrovirus in Europe 120
Decrease Paraoxonase-1 (PON-1) Activities in Neurodegenerative Diseases 120
SERUM GELATINASES LEVELS IN MULTIPLE SCLEROSIS PATIENTS DURING 21 MONTHS OF NATALIZUMAB TREATMENT 118
Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study 116
Cerebrospinal fluid oligoclonal free light chain profiles in AIDS 114
Specific antibodies reacting to JC polyomavirus capsid protein mimotopes in sera from multiple sclerosis and other neurological diseases-affected patients 114
INTRATHECAL PRODUCTION OF ACTIVE FORM OF MATRIX METALLOPROTEINASES-9 IN PATIENTS WITH MULTIPLE SCLEROSIS: PRELIMINARY RESULTS” 112
Increased Levels of Endothelin-1 in Cerebrospinal Fluid Are a Marker of Poor Visual Recovery after Optic Neuritis in Multiple Sclerosis Patients 112
Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies 111
Cerebrospinal fluid free Kappa and Lambda lights chains in MS. A qualitative analysis 111
Inflammation and axonal damage biomarkers in Multiple Sclerosis: new perspective on their role 111
null 110
Effect of HLA-G gene polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis. 110
Intrathecal synthesis of interleukin-12 in multiple sclerosis 109
Detection of Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response in a subset of patients with progressive forms of multiple sclerosis 109
null 109
Inverse association between CSF levels of solubile HLA-G and Fas molecules in MS patients with no evidence of MRI disease activity. 107
CSF levels and soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis 107
Influence of different strategies of volume replacement on the activity of matrix metalloproteinases: an in vitro and in vivo study 106
N-acetylaspartate, glutammate and aspartate levels in multiple sclerosis cerebrospinal fluid. 106
CEREBROSPINAL FLUID AND SERUM LEVELS OF ANTI-CHLAMYDIA PNEUMONIAE IGA IN PATIENTS WITH MULTIPLE SCLEROSIS - ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR IMPLEMENTING A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES. 106
Chlamydia pneumonia-specific CFS-restricted oligoclonal IgG bands are associated to a subset of patients with prosessive forms of multiple sclerosis. 105
Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epstein–Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study 104
Under the microscope: Focusing on Chlamydia pneumoniae infection and Multiple Sclerosis 104
null 104
Gelatinases: enzymatic activity as potential biomarker in multiple sclerosis 103
null 102
Potential role of soluble HLA-G molecules in multiple sclerosis 102
Matrix metalloproteinase-2 (MMP-2) immune functions via surface proteolytic shedding of HLA-G1 molecules 101
Soluble HLA class I molecules intrathecal production in multiple sclerosis. 101
Comparative analysis of environmental effects on multiple sclerosis development in Russian and Italian ethnic groups 100
Gelatinase: enzymatic activity as potential biomarker in multiple sclerosis 100
The Diagnostic Utility of Oligoclonal Bands in Multiple Sclerosis: A Time-Course Analysis 98
CSF levels of soluble classical HLA-I and non-classical HLA-G molecules in relapsing-remitting multiple sclerosis and their association with CSF IL-10 concentrations and MRI findings. 98
null 97
null 97
Multiple Sclerosis and HERV-W/MSRV: A Multicentric Study. Int J Biomed Sci. 97
EBV-specific intrathecal oligoclonal antibody response in multiple sclerosis patients 97
Totale 14.266
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.498
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 958
Totale 95.456
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.172 0 0 0 0 80 152 53 205 64 271 241 106
2021/20221.327 34 162 74 57 44 60 60 65 53 122 95 501
2022/20231.599 154 138 35 236 252 230 117 152 166 6 73 40
2023/2024956 79 88 45 25 101 187 27 85 35 25 28 231
2024/20253.531 76 79 275 142 447 302 117 159 679 385 494 376
2025/20264.286 999 379 835 1.331 742 0 0 0 0 0 0 0
Totale 19.482